Ronald E. Bruehlman - 16 Jun 2026 Form 4 Insider Report for GoodRx Holdings, Inc. (GDRX)

Reporting relationship: Director
Issuer ticker: GDRX
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 20:30:45 UTC
Prior SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Gracye Cheng, Attorney-in-Fact for Ronald E Bruehlman

Key filing fact

Ronald E. Bruehlman filed Form 4 for GoodRx Holdings, Inc. (GDRX) on 17 Jun 2026.

Key facts

This page summarizes Ronald E. Bruehlman's Form 4 filing for GoodRx Holdings, Inc. (GDRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 20:30.

Change

Previous filing in this sequence was filed on 29 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001604076 Primary reporting owner

Bruehlman Ronald E

Relationship: Director
Address: C/O GOODRX HOLDINGS, INC., 2701 OLYMPIC BOULEVARD, SANTA MONICA
Signature: /s/ Gracye Cheng, Attorney-in-Fact for Ronald E Bruehlman
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GDRX transaction

Class A Common Stock

Award

Transaction value
Shares: +73,434
Change %: +55%
Price: $0.000000^*
Shares after: 207,352
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).